Affordable Access

Publisher Website

Atrial flutter in patients treated for atrial fibrillation with propafenone

Authors
Journal
The American Journal of Cardiology
0002-9149
Publisher
Elsevier
Publication Date
Volume
66
Issue
7
Identifiers
DOI: 10.1016/0002-9149(90)91144-u
Disciplines
  • Medicine

Abstract

Abstract The class IC antiarrhythmic drug, propafenone, has been used successfully for the prevention of atrial fibrillation (AF), with few reported adverse cardiovascular effects. 1–3 Propafenone depresses the rate of rise and amplitude of phase 0 of the action potential, slowing conduction in the atrium. 4 Although it has mild β-adrenergic antagonist effects, it has relatively less effect on atrioventricular refractoriness, although in AF the ventricular response may slow. 5 With slower atrial arrhythmias such as atrial flutter, where less concealment of conduction occurs, it is possible that the same effect on ventricular rate may not be seen. This study defines the incidence of atrial flutter developing in a heterogeneous population of patients with recurrent AF and observes the ventricular response during this arrhythmia.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Atrial flutter in patients treated for atrial fibr...

on The American Journal of Cardio... Sep 15, 1990

Persistent atrial flutter in patients treated for...

on Journal of cardiovascular elec... September 1999

Proarrhythmia in patients treated for atrial fibri...

on Annals of Internal Medicine Jul 15, 1992
More articles like this..